AXSM vs. SMMT, GMAB, VTRS, ITCI, MRNA, RDY, CTLT, SRPT, PCVX, and QGEN
Should you be buying Axsome Therapeutics stock or one of its competitors? The main competitors of Axsome Therapeutics include Summit Therapeutics (SMMT), Genmab A/S (GMAB), Viatris (VTRS), Intra-Cellular Therapies (ITCI), Moderna (MRNA), Dr. Reddy's Laboratories (RDY), Catalent (CTLT), Sarepta Therapeutics (SRPT), Vaxcyte (PCVX), and Qiagen (QGEN). These companies are all part of the "pharmaceutical products" industry.
Axsome Therapeutics vs.
Axsome Therapeutics (NASDAQ:AXSM) and Summit Therapeutics (NASDAQ:SMMT) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, community ranking, media sentiment, analyst recommendations and dividends.
Axsome Therapeutics has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Axsome Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Axsome Therapeutics had 10 more articles in the media than Summit Therapeutics. MarketBeat recorded 17 mentions for Axsome Therapeutics and 7 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 0.72 beat Axsome Therapeutics' score of 0.43 indicating that Summit Therapeutics is being referred to more favorably in the news media.
Summit Therapeutics has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -91.87%. Summit Therapeutics' return on equity of -85.42% beat Axsome Therapeutics' return on equity.
Axsome Therapeutics received 150 more outperform votes than Summit Therapeutics when rated by MarketBeat users. Likewise, 69.48% of users gave Axsome Therapeutics an outperform vote while only 58.38% of users gave Summit Therapeutics an outperform vote.
Axsome Therapeutics currently has a consensus target price of $130.69, suggesting a potential upside of 27.55%. Summit Therapeutics has a consensus target price of $33.57, suggesting a potential upside of 42.86%. Given Summit Therapeutics' higher possible upside, analysts plainly believe Summit Therapeutics is more favorable than Axsome Therapeutics.
81.5% of Axsome Therapeutics shares are held by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are held by institutional investors. 22.4% of Axsome Therapeutics shares are held by company insiders. Comparatively, 88.3% of Summit Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Axsome Therapeutics has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500. Comparatively, Summit Therapeutics has a beta of -0.87, meaning that its share price is 187% less volatile than the S&P 500.
Summary
Axsome Therapeutics beats Summit Therapeutics on 11 of the 18 factors compared between the two stocks.
Get Axsome Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AXSM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Axsome Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:AXSM) was last updated on 1/29/2025 by MarketBeat.com Staff
